Mitochondria, the NLRP3 Inflammasome, and Sirtuins in Type 2 Diabetes: New Therapeutic TargetsReviewing Editors: <i>Markus Bachschmid, Dylan Burger, Vittorio Calabrese, Amadou Camara, Lukas Kubala, Giuseppe Poli, and Chandan K. Sen</i>
Susana Rovira‐Llopis, Nadezda Apostolova, Celia Bañuls et al.
Research Article — Peer-Reviewed Source
Original research published by Rovira‐Llopis et al. in Antioxidants and Redox Signaling. Redistributed under Open Access — see publisher for license terms. MedTech Research Group provides these references for informational purposes. We do not conduct original research. All studies are the work of their respective authors and institutions.
In this review article, we attempt to provide an overview of the existing literature concerning the crosstalk between mitochondrial impairment and the inflammasome, with particular attention to cellular and mitochondrial redox metabolism and the potential role of the NLRP3 inflammasome and sirtuins in the pathogenesis of type 2 diabetes. In addition, we discuss potential targets for therapeutic intervention based on these molecular interactions. Antioxid. Redox Signal. 29, 749-791.
Full text is available at the publisher.
Read at Publisher| DOI | 10.1089/ars.2017.7313 |
| Journal | Antioxidants and Redox Signaling |
| Year | 2017 |
| Authors | Susana Rovira‐Llopis, Nadezda Apostolova, Celia Bañuls, Jordi Muntané, Milagros Rocha, Víctor M. Víctor |
| License | Open Access — see publisher for license terms |
| Citations | 111 |